Mindray(SZ:300760) Sou Hu Cai Jing·2025-11-28 01:52Core Viewpoint - The chairman of Mindray Medical, Li Xiting, has increased his shareholding in the company, indicating confidence in the company's future performance and plans to continue purchasing shares in the coming months [2]. Group 1: Shareholding Changes - On November 27, Li Xiting acquired 152,300 shares at an average price of 196.86 yuan per share, totaling approximately 29.99 million yuan [2]. - Prior to the purchase, Li Xiting did not directly hold shares but controlled 327 million shares (26.98%) through the holding company Smartco Development, while his associate Xu Hang controlled 297 million shares (24.49%) through Magnifice (HK) [2]. - After the acquisition, Li Xiting directly holds 152,300 shares, maintaining the total control of 624 million shares (51.48%) with his associates [2]. Group 2: Future Plans - Li Xiting plans to continue increasing his shareholding by an additional 200 million yuan (including transaction fees) within six months starting from November 27, 2025 [2]. Group 3: Company Performance - For the first three quarters of 2025, Mindray Medical reported a revenue of 25.834 billion yuan, a year-on-year decrease of 12.38%, and a net profit attributable to shareholders of 7.570 billion yuan, down 28.83% year-on-year [6]. - The company's net profit excluding non-recurring items was 7.463 billion yuan, reflecting a decline of 28.50% year-on-year [6]. Group 4: Executive Compensation - Li Xiting's compensation over the past five years has totaled 128.29 million yuan, with annual salaries ranging from 24.94 million to 26.63 million yuan [4]. Group 5: Company Background - Mindray Medical was founded on January 25, 1999, and went public on October 16, 2018, focusing on the research, manufacturing, marketing, and service of medical devices [6].